CClinicalTrials.gg
Sign In
Status unknownNCT00186771Updated Jul 28, 2011

Magnetic Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia

A Phase 4 interventional study of Paired Pulse and Paired Pulse in Schizophrenia, sponsored by St. Joseph's Healthcare Hamilton. Status unknown at 2 sites in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-07-28.

Sponsored by St. Joseph's Healthcare Hamilton · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2011), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Schizophrenia is a chronic, severe, and disabling brain disease. Auditory hallucinations are the most frequent symptoms with an incident of 50% to 70% in patients.

Transcranial Magnetic Stimulation (TMS) can significantly reduce symptoms of schizophrenia. TMS is capable of inducing changes in the electrical activities of the brain in humans.

The purpose of this trial is to study the use of TMS to decrease auditory hallucinations in schizophrenia.

Read the detailed description

We hypothesize that: True treatment with rTMS will have significant decrease in auditory hallucinations versus sham treatment over the temporoparietal cortex.

FMRI will highlight areas of activation with auditory hallucinations distinct from the area identified by Hoffman's scalp based method.

Cortical inhibition as measured by paired pulse TMS will be increased after true TMS but not sham TMS.

02

Conditions studied

  • Schizophrenia

Keywords

  • Transcranial Magnetic Stimulation
  • Paired Pulse
03

In context

Hallucinations

132 studies on the registry are indexed under Hallucinations; 36 are open to participants now.

This study's planned enrollment of 10 is below the median of 50 across 112 interventional studies indexed under Hallucinations.

Browse Hallucinations studies →

Lead sponsor

St. Joseph's Healthcare Hamilton is the lead sponsor of 137 studies on the registry; 31 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Schizophrenia
  • Auditory hallucinations occuring more than 5 times per day
  • Adequate (6 weeks) trial of antipsychotic medication
  • Including at least 1 atypical antipsychotic medication
  • Medication stable for 4 weeks prior to commencement of the study
  • Competent to consent

Exclusion criteria

Exclusion Criteria:

  • history of seizure disorder in patient or first degree relative
  • recent head injury
  • Acute suicidality
  • Alcohol or substance abuse
  • Implanted pacemaker or metal in head or neck
  • Pregnancy
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
10 participants (estimated)

Study arms

  • Active comparator
    True Transcranial Magnetic Stimulation

    True treatment with TMS over the temporoparietal cortex.

    Device: Paired Pulse

  • Sham comparator
    Sham Transcranial Magnetic Stimulation

    Sham treatment with rTMS over the temporoparietal cortex.

    Device: Paired Pulse

Interventions

  • DevicePaired Pulse

    True treatment with rTMS over the temporoparietal cortex.

    Also known as: TMS

  • DevicePaired Pulse

    Sham treatment with rTMS over the temporoparietal cortex.

    Also known as: TMS

06

What researchers measure

Primary outcomes

  1. Hoffman Auditory Hallucination Scale

    A series of 7 questions to identify the intensity and severity of the hallucinations

    Time frame: weekly

Secondary outcomes

  1. Positive and Negative Syndrome Scale for Schizophrenia (PANSS)

    Time frame: 2 weeks

07

Study locations

2 of 2 sites recruiting
  • St. Joseph's Healthcare, rTMS Laboratory, 100 West Fifth Street
    Hamilton, Ontario L8N 3K7, Canada
    • Gary Hasey, MD · Principal investigator
    • Mohammad Warsi, MD · Sub investigator
    Recruiting
  • St. Joseph's Healthcare, rTMS Laboratory, 100 West Fifth Street
    Hamilton, Ontario L8N 3K7, Canada
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 28, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00186771
Lead sponsor
St. Joseph's Healthcare Hamilton
First posted
Sep 16, 2005
Start date
Nov 2004
Primary completion
Jan 2012 (estimated)
Completion
Jan 2015 (estimated)
Last update
Jul 28, 2011

Study contacts

Rose Marie Mueller, RN
Contact
rmueller@stjoes.ca
905-522-1155 ext. 36629
Sandra Chalmers, RN
Contact
schalmer@stjoes.ca
905-522-1155 ext. 35442
Gary Hasey, MD
principal investigator · St. Joseph's Health Care London

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Hallucinations→

Other studies from this sponsor

St. Joseph's Healthcare Hamilton

Start the discussion